- Home
- PBPB vs GOSS Comparison
PBPB vs GOSS Comparison
Compare PBPB & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBPB
- GOSS
- Stock Information
- Founded
- PBPB 1977
- GOSS 2015
- Country
- PBPB United States
- GOSS United States
- Employees
- PBPB N/A
- GOSS N/A
- Industry
- PBPB Restaurants
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- PBPB Consumer Discretionary
- GOSS Health Care
- Exchange
- PBPB Nasdaq
- GOSS Nasdaq
- Market Cap
- PBPB 305.0M
- GOSS 262.5M
- IPO Year
- PBPB 2013
- GOSS 2019
- Fundamental
- Price
- PBPB $11.54
- GOSS $1.40
- Analyst Decision
- PBPB Strong Buy
- GOSS Strong Buy
- Analyst Count
- PBPB 3
- GOSS 4
- Target Price
- PBPB $15.67
- GOSS $7.75
- AVG Volume (30 Days)
- PBPB 190.9K
- GOSS 1.3M
- Earning Date
- PBPB 08-07-2025
- GOSS 08-11-2025
- Dividend Yield
- PBPB N/A
- GOSS N/A
- EPS Growth
- PBPB 1009.90
- GOSS N/A
- EPS
- PBPB 1.39
- GOSS N/A
- Revenue
- PBPB $465,126,000.00
- GOSS $124,590,000.00
- Revenue This Year
- PBPB $4.74
- GOSS N/A
- Revenue Next Year
- PBPB $4.48
- GOSS $91.14
- P/E Ratio
- PBPB $8.28
- GOSS N/A
- Revenue Growth
- PBPB N/A
- GOSS N/A
- 52 Week Low
- PBPB $6.28
- GOSS $0.55
- 52 Week High
- PBPB $13.48
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- PBPB 63.95
- GOSS 57.95
- Support Level
- PBPB $10.51
- GOSS $1.22
- Resistance Level
- PBPB $11.26
- GOSS $1.36
- Average True Range (ATR)
- PBPB 0.37
- GOSS 0.08
- MACD
- PBPB -0.01
- GOSS -0.00
- Stochastic Oscillator
- PBPB 94.47
- GOSS 66.07
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.